Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data

Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data

Objectives Adjuvant trastuzumab in combination with chemotherapy has significantly improved survival in patients with HER2-positive early breast cancer but, since introduction in 2005, the 12 months duration has been questioned and trials have tested shorter durations.Methods and analysis A systemat...

Full description

Saved in:
Bibliographic Details
Main Authors: Roberto D’Amico, Valentina Guarneri, PierFranco Conte, Heikki Joensuu, Xavier Pivot, Vassilis Georgoulias, Louise Hiller, Janet A Dunn, Mubarak Patel, Teppo Huttunen, Helena M Earl, Dora Hatzidaki, Jean E Abraham, David Miles, David A Cameron, Andrew M Wardley
Format: Article
Language:English
Published: BMJ Publishing Group 2025-06-01
Series:BMJ Oncology
Online Access:https://bmjoncology.bmj.com/content/4/1/e000810.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjoncology.bmj.com/content/4/1/e000810.full

Similar Items